Circulating tumor DNA applications in monitoring the treatment of metastatic colorectal cancer patients.
Circulating tumor DNA
Colorectal cancer
Treatment monitoring.
Journal
Gastroenterology and hepatology from bed to bench
ISSN: 2008-2258
Titre abrégé: Gastroenterol Hepatol Bed Bench
Pays: Iran
ID NLM: 101525875
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
27
2
2020
Statut:
ppublish
Résumé
Colorectal cancer is the third most common cancer worldwide. New cancer treatment strategies such as monoclonal antibodies against growth factor and angiogenesis receptors have improved the overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC) patients. However, acquired resistance could happen after these therapies. Circulating tumor DNA (ctDNA) is the DNA fraction derived from tumor cells which could be applied as a non-invasive method for detecting tumor mutations before, during, and after therapies. Here, we reviewed most of the studies examining ctDNA as treatment monitoring in mCRC patients who receive different target therapies. Also, we compared ctDNA with other existing cancer-treatment monitoring methods.
Types de publication
Journal Article
Review
Langues
eng
Pagination
S14-S21Informations de copyright
©2019 RIGLD.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.